A systematic review of long-acting β2-agonists versus higher doses of inhaled corticosteroids in asthma

Pediatrics

Volumn 130, Issue 3, 2012, Pages

  Castro Rodriguez, Jose A ^a   Rodrigo, Gustavo J ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL CENTRAL DE LAS FUERZAS ARMADAS   (Uruguay)

Author keywords

Adolescents; Asthma; Children; Efficacy; Inhaled corticosteroids; LABA

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID DERIVATIVE; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; MOMETASONE FUROATE; SALMETEROL; SHORT ACTING DRUG;

ADOLESCENT; ASTHMA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; INFANT; LOW DRUG DOSE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE;

EID: 84865790306     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0162     Document Type: Review

References (34)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Update 2010. Available at: www.ginasthma.com. Accessed August 3, 2011
2. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, 2007. Available at: www.nhlbi.nih.gov. Accessed August 3, 2011
3. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2008;63(suppl 4):iv1-121
4. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with metaanalysis. Arch Dis Child. 2010;95(5):365-370
5. Sorkness CA, Lemanske RF Jr, Mauger DT, et al Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119(1):64-72
6. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2- agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;(4):CD005533
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting. Available at: www.ich.org/LOB/media/MEDIA436.pdf. Accessed July 21, 2011
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94
9. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011. Available at: www.cochrane-handbook.org. Accessed March 31, 2012
10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560
11. Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. Chichester (West Sussex), United Kingdom: John Wiley & Sons, Ltd.; 2009
12. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315 (7109):629-634
14. Verberne AAPH, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF; The Dutch Asthma Study Group. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med. 1998;158(1):213-219
15. Heuck C, Heickendorff L, Wolthers OD. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child. 2000;83(4):334-339
16. Vaessen-Verberne AAPH, van den Berg NJ, van Nierop JC, et al COMBO Study Group. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med. 2010;182(10):1221-1227
17. de Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol. 2009;20(8):763-771
18. Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Sträter C, Steinkamp G; VIAPAED Study Group. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol. 2009;44(11): 1132-1142
19. Murray CS, Custovic A, Lowe LA, et al. Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma. Allergy Asthma Proc. 2010;31(5): 415-421
20. GlaxoSmithKline Clinical Trial Register. SAM 40012 trial. Available at: http://gsk-clinicalstudyregister.com. Accessed July 7, 2011
21. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/ formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130(6):1733-1743
22. Lemanske RF Jr, Mauger DT, Sorkness CA, et al Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362(11):975-985
23. Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J Allergy Clin Immunol. 2011;127(1):145-152
24. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2): 76-83
25. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-178
26. Covar RA, Cool C, Szefler SJ. Progression of asthma in childhood. J Allergy Clin Immunol. 2005;115(4):700-707
27. Stoloff SW, Kelly HW. Updates on the use of inhaled corticosteroids in asthma. Curr Opin Allergy Clin Immunol. 2011;11(4):337-344
28. Johnson M. Molecular mechanisms of beta (2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006; 117:18-24
29. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2- agonists and corticosteroids. Eur Respir J. 2002;19(1):182-191
30. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics. 2000;106(1). Available at: www.pediatrics.org/cgi/content/full/106/1/e8
31. FDA Drug Safety Communication. New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). Available at: www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm200776.htm#-Ref252304350. Accessed October 12, 2010
32. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010; 362(13):1169-1171
33. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics. 2011;128(5). Available at: www.pediatrics.org/cgi/content/full/128/5/e1147
34. Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax. 2012;67(4):342-349